Literature DB >> 17046724

A delusion assessment scale for psychotic major depression: Reliability, validity, and utility.

Barnett S Meyers1, Judith English, Michelle Gabriele, Catherine Peasley-Miklus, Moonseong Heo, Alastair J Flint, Benoit H Mulsant, Anthony J Rothschild.   

Abstract

BACKGROUND: Although delusions are the hallmark of major depression with psychotic features, a scale to measure the intensity of beliefs across multiple delusional domains in this condition has been unavailable. The development and assessment of the Delusional Assessment Scale (DAS) are described.
METHODS: Scale items were selected initially based on previous studies of delusional ideation in schizophrenia. A three-point item to assess mood congruence was added. A 15-item scale was assessed in 92 subjects participating in the four-site collaborative study of the pharmacotherapy of major depression with psychotic features. Maximum likelihood method was used to determine scale factors. The internal consistency of these factors was determined. Comparisons between scale scores and ratings from the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962) were used to assess convergent and discriminant validity.
RESULTS: The data were fit by a five-factors model (impact, conviction, disorganization, bizarreness, and extension). Inter-rater reliability of the five factors ranged from .77 for conviction and .74 for impact to .37 for disorganization. Internal consistency for each of the five factors was > or =.72. Scores on specific domains were significantly correlated with the BPRS unusual thought content item and positive symptom subscale scores.
CONCLUSIONS: The DAS is a reliable measure of 5 delusional domains.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046724     DOI: 10.1016/j.biopsych.2006.05.033

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  14 in total

1.  Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.

Authors:  Alastair J Flint; Barnett S Meyers; Anthony J Rothschild; Ellen M Whyte; George S Alexopoulos; Matthew V Rudorfer; Patricia Marino; Samprit Banerjee; Cristina D Pollari; Yiyuan Wu; Aristotle N Voineskos; Benoit H Mulsant
Journal:  JAMA       Date:  2019-08-20       Impact factor: 56.272

2.  The psychometric properties of the Peters et al. delusions inventory (PDI) in Taiwan: reliability, validity, and utility.

Authors:  Yu-Chen Kao; Tzong-Shi Wang; Chien-Wen Lu; Tsung-Hsing Cheng; Yia-Ping Liu
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-08-23       Impact factor: 4.328

3.  Effect of age on the frequency of anxiety disorders in major depression with psychotic features.

Authors:  Alastair J Flint; Catherine Peasley-Miklus; Eros Papademetriou; Barnett S Meyers; Benoit H Mulsant; Anthony J Rothschild; Ellen M Whyte
Journal:  Am J Geriatr Psychiatry       Date:  2010-05       Impact factor: 4.105

4.  Measuring psychotic depression.

Authors:  S D Østergaard; B S Meyers; A J Flint; B H Mulsant; E M Whyte; C M Ulbricht; P Bech; A J Rothschild
Journal:  Acta Psychiatr Scand       Date:  2013-06-25       Impact factor: 6.392

5.  Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.

Authors:  Judith Weissman; Alastair Flint; Barnett Meyers; Samiran Ghosh; Benoit Mulsant; Anthony Rothschild; Ellen Whyte
Journal:  Psychiatry Res       Date:  2012-03-31       Impact factor: 3.222

6.  Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.

Authors:  Daniel M Blumberger; Benoit H Mulsant; Chetachi Emeremni; Patricia Houck; Carmen Andreescu; Sati Mazumdar; Ellen Whyte; Anthony J Rothschild; Alastair J Flint; Barnett S Meyers
Journal:  J Psychiatr Res       Date:  2011-02-05       Impact factor: 4.791

7.  Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.

Authors:  Søren D Østergaard; Barnett S Meyers; Alastair J Flint; Benoit H Mulsant; Ellen M Whyte; Christine M Ulbricht; Per Bech; Anthony J Rothschild
Journal:  J Affect Disord       Date:  2014-01-02       Impact factor: 4.839

8.  Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?

Authors:  Taafoi S Kamara; Ellen M Whyte; Benoit H Mulsant; Catherine Peasley-Miklus; Anthony J Rothschild; Alastair J Flint; Moonseong Heo; Eros Papademetriou; Erin R Mathis; Barnett S Meyers
Journal:  J Affect Disord       Date:  2008-06-04       Impact factor: 4.839

9.  A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).

Authors:  Barnett S Meyers; Alastair J Flint; Anthony J Rothschild; Benoit H Mulsant; Ellen M Whyte; Catherine Peasley-Miklus; Eros Papademetriou; Andrew C Leon; Moonseong Heo
Journal:  Arch Gen Psychiatry       Date:  2009-08

10.  A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.

Authors:  Kristina M Deligiannidis; Anthony J Rothschild; Bruce A Barton; Aimee R Kroll-Desrosiers; Barnett S Meyers; Alastair J Flint; Ellen M Whyte; Benoit H Mulsant
Journal:  J Clin Psychiatry       Date:  2013-10       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.